

デンマーク・日本の有識者による乾癬に関するディスカッションフォーラムで島田学長が講演！

令和 4 年 9 月 1 日(木)に開催されたデンマーク・日本の有識者による乾癬※に関するディスカッションフォーラム(Non-Communicable Disease - Denmark Japan Stakeholder Discussion Forum)で島田眞路学長が講演しました。

フォーラムには、島田学長をはじめ、マグヌス・ホイニッケ デンマーク王国保健大臣、スベント セルキア デンマーク王国保健省長官、ピーター・タクソー・イェンセン 在日デンマーク王国大使、クリストフ・ブルドン レオファーマ CEO(製薬会社)らが参加しました。

島田学長は、皮膚科医として、世界保健機関(WHO) 乾癬に関するグローバルレポートを踏まえ、日本における乾癬配合外用薬のドラッグラグについて講演しました。また、デンマークと日本で行っている乾癬患者の自立と QOL(生活の質)の向上、医療措置による医療費負担に貢献するための働きかけやアイデアについて、参加者と意見交換しました。

講演の内容については、下記資料をご覧ください。

※乾癬は、皮膚、爪、関節を侵すことがあり、慢性的で痛みを伴い、外観を損ない、障害をもたらす非感染性疾患であり、治療法が確立されていない。この病気は、生活の質に悪影響を及ぼします。



Non-Communicable Disease – Denmark Japan Stakeholder Discussion Forum

Engaging and Empowering Patients

Thursday September 1, 2022
15:00 – 16:30

NTT Medical Center (Input Address and Map link)

Roundtable Purpose

- **Increase understanding** of what Japan and Denmark is doing in the fields of fighting Non-Communicable Disease.
- **Share perspectives and ideas** on what stakeholders in Denmark and Japan are doing to contribute to improved patient independence and Quality of Life as well as controlling health expenditure through preventive and medical measures.
- **Create new connections** and inspire participants from Japan and Denmark in the fight against NCDs





Background

According to the World Health Organization (WHO), globally NCDs claim 41 million lives yearly, accounting for ~70% of annual deaths, pre COVID-19.

NCDs are defined by the WHO as a group of diseases including cancer, diabetes, cardiovascular disease, allergy, respiratory disease, and mental health that are not-transmittable between individuals and caused by overweight/obesity, smoking, excessive drinking, and air pollution. NCDs are also characterized by oftentimes being preventable diseases that can be avoided or mitigated through positive changes in lifestyle.

In both Denmark and Japan, main causes of death have shifted from communicable disease before WWII to currently being NCDs with cancer and cardiovascular diseases the two highest causes of deaths in both countries.

In addition to the increased risk of a preventable and premature death, NCDs impacts the Quality of Life of the individual and place a burden on the families. To society, NCDs place a large burden on the healthcare systems. According to statistics compiled by the Ministry of Health, Labour and Welfare in Japan, in 2018, the cost of cardiovascular diseases, cancer, diabetes, psychiatric medicine and respiratory diseases together accounted for more than 50% of the healthcare expenditure in Japan. ***Also, non-fatal diseases also carries a large societal burden and, for instance, skin diseases such as Psoriasis and Atopic Dermatitis continues to be the 4th leading cause of nonfatal disease burden world-wide as reported by Seth et al in the journal Current Dermatology in 2017.***

One of the most important things in managing NCDs are to engage and empower the patients to take control and ownership of the disease and support them in making the lifestyle changes necessary to improve their disease.

We hope to gather physicians, policy makers, government and representatives of industry from Denmark and Japan for an open and stimulating discussion on how to support patients in controlling and preventing NCDs, exchanging views across sectors and country borders.

The event is hosted by the Danish Ministry of Health and the Danish Embassy in Tokyo, supported by the Japan Ministry of Health, Labour and Welfare.



Program Draft

Program	Time	Details
Opening	15:00-15:05	The Danish Health Minister gives opening remarks
Key Note Lecture 1	15:05-15:15	NCDs in Denmark - Initiatives Healthcare Denmark Jakob Skaarup Nielsen
Key Note Lecture 2	15:15-15:30	NCDs in Japan – Initiatives MHLW (TBC) Speaker TBD
Roundtable Initial Statements (2 min each)	15:30-16:00	Position Statements Roundtable Participants
Discussion	16:00–16:25	Discussion Moderator: HCD
Closing	16:25-16:30	Closing Danish Ambassador Peter Taksøe-Jensen



Participant profiles - Denmark



Mr. Magnus Heunicke, Minister of Health

Magnus Heunicke has been the Minister for Health of the Kingdom of Denmark since 2019 and also served as Minister for Senior Citizens between 2019-2021. Previously, he was Minister for Transport.



Mr. Heunicke is a social democrat and before entering politics he worked as a journalist.



Mr. Svend Særkjær, Permanent Secretary of Health

Mr. Særkjær took the position of Permanent Secretary of Health in the Danish Ministry of Health in 2021. Before that he was CEO of Region Northern Denmark and Region Capital Region. He has a long career in the Danish Ministry of Health working with issues such as disease prevention, welfare support among others.



He graduated with a master in political science from the University of Århus.



Mr. Peter Taksøe Jensen, Ambassador to Japan

Mr. Taksøe Jensen was appointed as Ambassador of the Kingdom of Denmark to Japan in 2019. He has a long background of service in the foreign ministry having previously served as Ambassador to the US and India.



He holds a law degree from the University of Copenhagen.



Dr. Henrik Ullum, CEO, Statens Serum Institut

Statens Serum Institut (SSI) is under the auspices of the Danish Ministry of Health. SSI's main duty is to ensure preparedness against infectious diseases and biological threats as well as control of congenital disorders. SSI also houses the Danish National Biobank which stores more than 22 million biological samples, such as serum, plasma, buffy coat, whole blood and DNA.

Dr. Ullum is the CEO of Statens Serum Institut (SSI) and has been so since December 2020. As CEO, Dr. Ullum has the overall responsibility of the day-to-day running of SSI. He has a medical degree from the University of Copenhagen where he was a professor from 2014 to 2020.



Mr. Jakob Skaarup Nielsen, CEO, Healthcare DENMARK

Healthcare DENMARK is a non-profit public-private partnership. As Denmark's national branding organisation on healthcare and life science, they are the gateway for international stakeholders to Danish healthcare expertise and innovation. They offer an exclusive opportunity to experience Danish healthcare solutions by uniting national and international stakeholders.



HRH The Crown Princess of Denmark is patron for Healthcare DENMARK.

Their partners include the Ministry of Health and other public institutions, leading Danish universities, and innovative private companies within pharma, medtech and e-health.

Jakob was appointed CEO of Healthcare DENMARK in 2021 and before that he has a long career in the Ministry of Foreign Affairs, including a four year posting to the Embassy of Denmark in Tokyo. Jakob holds a Master degree in Economics, Business Administration and Commercial Law from Aarhus University, School of Business.



Mr. Lars Fruergaard Jørgensen, CEO, Novo Nordisk

Novo Nordisk is a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Their purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases. They do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat.



Novo Nordisk employs more than 47,000 people in 80 offices around the world, including Japan, and market our products in 168 countries.

Mr Jørgensen joined Novo Nordisk in 1991 as an economist in Health Care, Economy & Planning and has over the years completed overseas postings in the Netherlands, the US and Japan. Mr Jørgensen was appointed president and chief executive officer in January 2017.



Dr. Deborah Dunsire, CEO, Lundbeck Pharmaceuticals

Lundbeck is a global pharmaceutical company specialized in developing innovative treatments for brain diseases. For more than 70 years, millions of people have been treated with their products and their development and distribution of pioneering therapies continues to make a difference to people worldwide.



Lundbeck employs over 5,300 people across the world, including Japan and their products are registered in more than 100 countries globally.

Dr. Dunsire is a Doctor of Medicine, University of Witwatersrand. She has more than 20 years of experience in the scientific, clinical, operational, and commercial aspects of the biological/pharmaceutical business. She was appointed CEO of Lundbeck in 2018.

Dr. Dunsire is a citizen of South Africa.



Mr. Christophe Bourdon, CEO, Leo Pharmaceuticals

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities.

LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world.

In 2022, Christophe Bourdon joined LEO Pharma as CEO. His previous roles include CEO of Orphazyme A/S, Senior Vice President and General Manager of the Oncology Business at the US biotech company Amgen where he also led commercialization planning of top-selling drugs on the global market.

He holds an MBA from IMD Business School in Switzerland and a BA from ISG in France. Mr. Bourdon is a citizen of France.

Participant profiles – Japan

To be announced

**Shinji Shimada, President
University of Yamanashi**



World Health Organization(WHO) Global Report on Psoriasis

Psoriasis, which can involve the skin, nails and joints, is a chronic, painful, disfiguring and disabling noncommunicable disease (NCD) for which there is no cure. It negatively impacts on quality of life. Some of those who suffer from the disease develop chronic, inflammatory arthritis (psoriatic arthritis) that leads to joint deformations and disability. People with psoriasis are also reported to be at increased risk of developing other serious clinical conditions such as cardiovascular and other NCDs.

People with psoriasis are frequently stigmatized and excluded from normal social environments. They commonly report experiencing loneliness, isolation and feelings of being unattractive. As such, there is a significant cost to mental well-being, such as higher rates of depression. Disability, lost opportunities in professional life and high treatment expenses can add to the significant socioeconomic burden for people with psoriasis. Costs are substantial also for the health care system.

In response to the resolution on psoriasis adopted by the 67th World Health Assembly in 2014 (WHA 67.9), WHO has developed a Global report on psoriasis, and included information about psoriasis on this web site, to help raise awareness of the range of ways that psoriasis can affect peoples' lives. The report intends to empower policy-makers with practical solutions to improve the health care and social inclusion of people living with psoriasis.

Dr Oleg Chestnov
Assistant Director-General
Noncommunicable Diseases and
Mental Health
World Health Organization




Global report on **PSORIASIS**



Drug Lag for Combined Topical Drug for Psoriasis in Japan



Combined topical drugs for psoriasis were launched in Japan 13 years late for Ointment, 10 years late for Gel, and 6 years late for Foam. However, in the last few years, the time to market in Japan has been shortened.



※ FDC: Fixed dose combination


LEO Foundation Awards

A boost to young talents

The LEO Foundation Awards – worth USD 100,000 – recognize outstanding young researchers and scientists from around the world whose work represents an extraordinary contribution to skin research and has the potential to pave the way for new and improved treatments for skin diseases.

The award was born out of the aim of advancing the understanding and treatment of skin diseases and strengthening the pipeline of excellent dermatology researchers. It recognizes promising young talents and hopefully provides a boost to their future careers.

The award is well aligned with the Foundation's goal of continually promoting and advancing skin research. Since the first LEO Foundation Award in 2008, around 30 scientists have received the award.



LEO FOUNDATION



山梨大学 学長
島田 眞路

世界保健機関（WHO） 乾癬に関するグローバルレポート

乾癬は、皮膚、爪、関節を侵すことがあり、慢性的で痛みを伴い、外観を損ない、障害をもたらす非感染性疾患（NCD）であり、治療法が確立されていない。この病気は、生活の質に悪影響を及ぼします。本疾患に罹患した方の中には、関節の変形や障害をもたらす慢性炎症性関節炎（乾癬性関節炎）を発症する方がいらっしゃいます。また、乾癬の患者様は、心血管疾患やその他のNCDといった他の重篤な臨床症状を発症するリスクが高いことが報告されています。

乾癬の患者様は、しばしばスティグマの対象となり、通常の世界環境から排除されることがあります。彼らは一般的に、孤独感、孤立感、魅力のなさを経験していると報告しています。そのため、うつ病の罹患率が高くなるなど、精神的な幸福に大きな代償を払っています。障害、職業生活における機会損失、高額な治療費は、乾癬患者にとって大きな社会経済的負担となります。また、医療制度にも大きな負担がかかっています。

2014年の第67回世界保健総会で採択された乾癬に関する決議（WHA 67.9）を受けて、WHOは乾癬に関するグローバルレポートを作成し、本ウェブサイトにて乾癬に関する情報を掲載し、乾癬が人々の生活に及ぼす様々な影響についての認識を高めることに貢献しています。この報告書は、乾癬と共に生きる人々のヘルスケアと社会的包摂を改善するための実践的な解決策を政策立案者に提供することを意図しています。



Global report on PSORIASIS



Dr Oleg Chestnov
副局長
非感染性疾患とメンタルヘルス
世界保健機関（WHO）




日本における乾癬配合外用薬のドラッグラグについて



乾癬の配合外用剤は、日本では軟膏が13年、ゲルが10年、フォームが6年遅れで発売されました。加えて、乾癬に対する抗体製剤においても、抗TNF- α 抗体製剤も12年遅れで発売されましたが、抗TNF- α 受容体抗体製剤は今もなお発売されていません。しかし、ここ数年、日本での上市までの期間が短縮されてきています。

Global
Japan



LEO財団賞

若い才能を後押しする

LEO Foundation Awards は、皮膚科学研究への卓越した貢献と、皮膚疾患の新たな治療法の可能性を秘めた世界中の優れた若手研究者や科学者を表彰するもので、10万米ドルの賞金が授与されます。

この賞は、皮膚疾患の理解と治療を促進し、優秀な皮膚科学研究者のパイプラインを強化することを目的として生まれました。この賞は、将来有望な若い才能を認め、彼らの将来のキャリアに弾みをつけることを期待しています。

この賞は、皮膚科学の研究を継続的に推進し、発展させるという当財団の目標によく合致しています。

2008年の第1回LEO財団賞以来、約30名の科学者が同賞を受賞しています。



LEO

LEO FOUNDATION